Bharat Immunologicals & Biologicals Q3 results, quarter to Dec 2022
BSE: 524663Pharmaceuticals & BiotechnologySmall Cap
Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1994
Last close ₹9.19up ₹0.32 (3.61%)
Share price at the BSE close on 2 Nov 2026. Previous close ₹8.87.
2 Nov: open ₹9.00, high ₹9.30, low ₹8.71
52-week range of traded prices to 2 Nov 2026
₹7.11Low, 6 Oct 2026₹22.61High, 23 Dec 2025
- Under BSE's graded surveillance, stage 0, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹40 Cr3,103rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 14,200
Bharat Immunologicals & Biologicals filed its Q3 results for the quarter to Dec 2022 on 16 Feb 2023 at 10:30 am, standalone: the listed company alone, without its subsidiaries.
Q3 results, quarter to Dec 2022
₹ crore.Bharat Immunologicals & Biologicals annual results and balance sheet
- RevenueRevenue from operations. Money earned from selling the company's goods and services in the period. Revenue from operations in the glossary
- ₹0.00 Cr−100.0% on a year ago · −100.0% on the quarter beforeChange on a year ago and on the quarter before. The change against the same quarter a year before: (this quarter's figure less that quarter's) divided by that quarter's, times 100. The change on the quarter before is the same sum against the quarter just before, taken as this quarter's results restate it where the company restated it: this quarter's year to date less this quarter. Left out where either figure is a loss, where the restatement covers two or more earlier quarters without saying which, or across a change of basis named under the table, on the lines it affects.
- Operating profitOperating profit before depreciation (EBITDA). Revenue less operating expenses: what the business earns from its operations before depreciation, interest and tax. Operating profit before depreciation (EBITDA) in the glossary
- −₹4.73 Cr
- Net profitNet profit. What is left of revenue and other income after every cost, interest and tax. Net profit in the glossary
- −₹4.68 Cr
- Earnings per shareEarnings per share. Profit belonging to shareholders divided by the number of shares, restated for later splits and bonuses so they do not break the line. Earnings per share in the glossary
- −₹1.08
From revenue to net profit, ₹ crore
- Revenue0.0
- Materials and goods+1.3
- Employee costs−4.1
- Other expenses−2.0
- Operating profit−4.7
- Depreciation0.0
- Other income+0.1
- Finance costs−1.7
- Profit before tax−6.3
- Tax+1.6
- Net profit−4.7
Bharat Immunologicals & Biologicals results by quarter
Standalone: the listed company alone, without its subsidiaries. Latest quarter to Dec 2022. Results for the quarter to Mar 2023 were due by 30 May 2023, 60 days after it ends. Every company's dates are on the results calendar.Results filings and date
Revenue and net profit by quarter, ₹ crore
- Revenue
- Net profit
- Loss
Peak revenue ₹26 Cr, quarter to Sep 2022; lowest ₹0.00 Cr, quarter to Dec 2022A loss in 8 of the 9 quarters with results on record
Operating and net margin by quarter, per cent
- Operating marginOperating margin. Operating profit before depreciation as a percentage of revenue: how much of each rupee of sales is left after running costs. Operating margin in the glossary
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
| ₹ crore | Mar 2018 | Jun 2018Q1 | Sep 2018 | Dec 2018Q3 | Mar 2019 | Jun 2019Q1 | Sep 2019 | Dec 2019Q3 | Mar 2020 | Jun 2020Q1 | Sep 2020 | Dec 2020Q3 | Mar 2021 | Jun 2021Q1 | Sep 2021 | Dec 2021Q3 | Mar 2022 | Jun 2022worked out | Sep 2022 | Dec 2022Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 21.7 | 0.1 | 4.7 | 8.3 | 70.6 | 7.0 | 8.1 | 28.5 | – | 19.2 | 25.4 | 25.2 | – | 14.2 | 24.7 | 17.4 | – | 10.5what Revenue from operations, Jun 2022, includes. Not filed on its own: worked out as the six months to Sep 2022 the company filed, less the three months to Sep 2022. | 26.5 | 0.0 |
| Operating expenses. What the business spent to run itself in the period, materials, staff and other costs, before depreciation, interest and tax. Operating expenses in the glossary | 26.0 | 1.5 | 8.3 | 7.8 | 74.9 | 12.7 | 14.8 | 30.5 | – | 18.5 | 29.9 | 27.5 | – | 13.2 | 28.2 | 16.7 | – | 15.3 | 29.0 | 4.7 |
| Materials and goods boughtCost of materials and goods. Raw materials used and goods bought for resale in the period, adjusted for the change in stock held. Cost of materials and goods in the glossary | 21.9 | −2.3 | 3.9 | 4.4 | 67.3 | 7.0 | 10.2 | 24.4 | – | 13.8 | 23.2 | 22.9 | – | 8.9 | 22.0 | 9.3 | – | 8.1 | 24.4 | −1.3 |
| Employee costsEmployee costs. Salaries, wages, bonuses and other benefits paid to staff in the period. Employee costs in the glossary | 3.3 | 2.2 | 2.3 | 2.3 | 2.5 | 2.6 | 2.6 | 2.7 | – | 1.6 | 3.5 | 2.6 | – | 2.8 | 3.1 | 3.2 | – | 4.0 | 3.9 | 4.1 |
| Other expensesOther expenses. Every operating cost besides materials and staff: power, rent, freight, repairs, marketing and the like. Other expenses in the glossary | 0.8 | 1.6 | 2.1 | 1.1 | 5.1 | 3.1 | 2.0 | 3.5 | – | 3.1 | 3.1 | 1.9 | – | 1.5 | 3.2 | 4.3 | – | 3.3 | 0.7 | 2.0 |
| Operating profit before depreciation | −4.3 | −1.4 | −3.6 | 0.5 | −4.3 | −5.7 | −6.7 | −2.0 | – | 0.6 | −4.5 | −2.3 | – | 1.0 | −3.5 | 0.7 | – | −4.8 | −2.5 | −4.7 |
| Operating margin | −19.8% | −1,663.4% | −77.3% | 5.5% | −6.1% | −81.9% | −82.6% | −7.1% | – | 3.3% | −17.7% | −9.0% | – | 7.3% | −14.1% | 3.9% | – | −46.1% | −9.4% | – |
| Depreciation and amortisationDepreciation and amortisation. The part of the cost of plant, buildings and other long-lived assets charged against each year they are used. Depreciation and amortisation in the glossary | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.2 | 0.1 | 0.1 | – | 0.1 | 0.1 | 0.1 | – | 0.1 | 0.1 | 0.0 | – | 0.0 | 0.0 | 0.0 |
| Other incomeOther income. Income from outside the main business, such as interest on deposits, dividends received and gains on investments. Other income in the glossary | 0.6 | 0.3 | 0.1 | 0.1 | 2.1 | 1.8 | 0.2 | 0.5 | – | −0.6 | 0.1 | 1.2 | – | 0.2 | 0.2 | 0.1 | – | 0.1 | 0.3 | 0.1 |
| Finance costsFinance costs. Interest and the other costs of borrowing in the period. Finance costs in the glossary | 0.4 | 0.0 | 0.1 | 0.4 | 0.9 | 0.9 | 1.2 | 1.6 | – | 1.1 | 1.2 | 1.3 | – | 1.2 | 1.2 | 1.5 | – | 1.6 | 1.7 | 1.7 |
| One-off itemsExceptional items. Gains or losses the company reports separately because they are not expected to recur, such as selling a business or writing down an asset. Exceptional items in the glossary | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | 0.0 | 0.0 | 0.0 | – | 0.0 | 0.0 | 0.0 | – | 0.0 | 0.0 | 0.0 |
| Profit before tax | −4.1 | −1.2 | −3.7 | 0.0 | −3.1 | −5.0 | −7.8 | −3.2 | – | −1.1 | −5.6 | −2.4 | – | 0.1 | −4.6 | −0.8 | – | −6.3 | −4.0 | −6.3 |
| −2.8 | −0.4 | −1.2 | 0.0 | −0.9 | 1.0 | −2.2 | −0.9 | – | −0.3 | −1.7 | −0.5 | – | −1.9 | 4.8 | −0.1 | – | −1.3 | −0.9 | −1.6 | |
| Tax rateEffective tax rate. Tax charged as a percentage of profit before tax. Effective tax rate in the glossary | – | – | – | 14.9% | – | – | – | – | – | – | – | – | – | −2,539.0% | – | – | – | – | – | – |
| Net profit | −1.3 | −0.8 | −2.5 | 0.0 | −2.2 | −6.0 | −5.7 | −2.4 | – | −0.8 | −3.9 | −1.9 | – | 1.9 | −9.4 | −0.7 | – | −5.0 | −3.1 | −4.7 |
| Other comprehensive incomeOther comprehensive income. Gains and losses booked straight to net worth rather than through profit, such as changes in the value of some investments, pension plans and currency translation. Other comprehensive income in the glossary | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | – | 0.0 | 0.0 | 0.0 | – | 0.0 | 0.0 | 0.0 | – | 0.0 | 0.0 | 0.0 |
| Total comprehensive incomeTotal comprehensive income. Net profit plus other comprehensive income. Total comprehensive income in the glossary | – | −0.8 | −2.5 | 0.0 | −2.2 | −6.0 | −5.5 | −2.4 | – | −0.8 | −3.9 | −1.9 | – | 1.9 | −9.4 | −0.7 | – | −5.0 | −3.1 | −4.7 |
| Net margin | −6.0% | −953.2% | −53.6% | 0.2% | −3.2% | −85.2% | −69.9% | −8.3% | – | −4.1% | −15.2% | −7.5% | – | 13.6% | −37.9% | −3.8% | – | −47.7% | −11.6% | – |
| Earnings per share | −₹0.30 | −₹0.19 | −₹0.58 | – | −₹0.52 | – | −₹1.28 | −₹0.54 | – | −₹0.18 | −₹0.90 | −₹0.44 | – | ₹0.45 | −₹2.17 | −₹0.08 | – | −₹1.16 | −₹0.71 | −₹1.08 |
Earnings per share in rupees, restated for later splits and bonuses. No results on record for the quarters to Mar 2020, Mar 2021 and Mar 2022.
The quarter to Jun 2019 was restated in the company's filing of 6 Nov 2019. The table shows the restated figures.
Segment results by quarter
Standalone, ₹ crore, quarters to Dec 2022.Bharat Immunologicals & Biologicals segment results by year
ORAL POLIO VACCINE
Revenue, ₹ croreProfit, ₹ croreZINC DISPERSIBLE TABLETS
Revenue, ₹ croreProfit, ₹ croreBIB SWEET TABLETS
Revenue, ₹ croreProfit, ₹ croreBIBSANIT
Revenue, ₹ croreProfit, ₹ crorePROJECTS
Revenue, ₹ croreProfit, ₹ crore
| ₹ crore | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue of all businesses | 19 | 25 | 25 | – | 14 | 25 | 17 | – | – | 26 | – |
| Company revenue, as in its resultsCompany revenue. The company's revenue from operations for the period in its results, on the same accounts as its segments. It is below the businesses' sum where they sell to one another, or where the segments include a business the results report as discontinued. | 19 | 25 | 25 | – | 14 | 25 | 17 | – | – | 26 | 0 |
| Revenue | 19 | 25 | 25 | – | 14 | 25 | 17 | – | – | 26 | 0 |
| Revenue growthSegment revenue growth, year on year. The change in the segment's revenue from the same period a year before, as a percentage of that earlier revenue: a year against the year before, a quarter against the same quarter. Segment revenue growth, year on year in the glossary | 173.2% | 212.7% | −11.7% | – | −25.8% | −2.5% | −30.8% | – | – | 7.2% | −100.0% |
| ProfitSegment profit. What the business earned before tax and finance costs, as the company measures each of its businesses. Segment profit in the glossary | −1 | −6 | −2 | – | 2 | −5 | 0 | – | – | −3 | −5 |
| MarginSegment margin. Segment profit as a percentage of the segment's revenue. Segment margin in the glossary | −5.7% | −21.9% | −9.6% | – | 13.6% | −18.4% | −2.5% | – | – | −11.6% | – |
| AssetsSegment assets. What the company holds for this business at the period end: plant, stock, receivables and the like. Segment assets in the glossary | 94 | 44 | 38 | – | 36 | 126 | 191 | – | – | 191 | 192 |
| LiabilitiesSegment liabilities. What this business owes at the period end, such as payments due to suppliers. Segment liabilities in the glossary | 46 | – | – | – | – | – | 135 | – | – | – | 0 |
| Capital employedCapital employed in the segment. Segment assets less segment liabilities at the period end: the money tied up in this business. Capital employed in the segment in the glossary | 48 | – | – | – | – | – | 56 | – | – | – | 191 |
| Revenue | 0 | 0 | 0 | – | – | 0 | – | – | – | 0 | 0 |
| Revenue | – | 0 | 0 | – | 0 | 0 | 0 | – | – | 0 | 0 |
| Revenue | 0 | 0 | 0 | – | 0 | 0 | 0 | – | – | 0 | 0 |
| – | – | – | – | – | – | – | – | – | – | 0 | |
| – | 0 | 0 | – | – | 0 | – | – | – | 0 | – | |
| – | – | – | – | – | – | 0 | – | – | – | – | |
| 0 | – | – | – | – | – | – | – | – | – | – |
Profit is before tax and finance costs, the way companies report their segments.